Adropin and Irisin as Potential Patentable Biomarkers in Metabolic-Associated Fatty Liver Disease: Current Evidence...

Metabolic-associated fatty liver disease (MAFLD), formerly nonalcoholic fatty liver disease (NAFLD), is the most common long-term liver disease. It affects 25% of adults and is a major cause of liver disease worldwide. Its rise is linked to rising obesity, especially in Western nations. Unfortunately, no MAFLD medication works. Patents and intellectual property are essential to developing effective cures and protecting new ideas. Long-term aerobic activity can raise hepatic triglycerides and lower visceral fat without weight loss. Due to its complexity, MAFLD is difficult to diagnose and treat. There are no inexpensive, reliable imaging diagnostics or non-invasive biomarkers. Too many liver lipids can cause lipotoxicity. This can cause NASH, liver fibrosis, and hepatocellular cancer. More serious MAFLD and NASH accelerate necroinflammation and fibrosis. This shows how important good signals are for diagnosing and treating your ailment. Invasive liver biopsies aren't helpful since people don't handle them well. We need reliable non-invasive assays to detect MAFLD early, improve clinical trials, and confirm therapy. Irisin, a hormone that boosts energy expenditure and mimics brown fat, is elevated in physically active people. Patenting discoveries about it could speed up research and the development of tailored treatments. Patenting innovative biomarker research concepts and intellectual property is essential to combating MAFLD. This will also enable novel illness diagnosis and treatment methods. Our approach must involve new MAFLD diagnosis and treatment methods and patent issues to address all its effects.